Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC cut its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 7.4% in the 4th quarter, HoldingsChannel reports. The fund owned 36,640 shares of the specialty pharmaceutical company’s stock after selling 2,943 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Supernus Pharmaceuticals were worth $1,060,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 0.5% in the third quarter. Vanguard Group Inc. now owns 6,072,180 shares of the specialty pharmaceutical company’s stock valued at $167,410,000 after acquiring an additional 28,711 shares in the last quarter. Armistice Capital LLC boosted its holdings in shares of Supernus Pharmaceuticals by 1.1% in the third quarter. Armistice Capital LLC now owns 5,092,000 shares of the specialty pharmaceutical company’s stock valued at $140,386,000 after acquiring an additional 56,000 shares in the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Supernus Pharmaceuticals by 8.6% in the third quarter. Loomis Sayles & Co. L P now owns 1,730,269 shares of the specialty pharmaceutical company’s stock valued at $47,703,000 after acquiring an additional 136,964 shares in the last quarter. Polar Capital Holdings Plc boosted its holdings in shares of Supernus Pharmaceuticals by 10.0% in the third quarter. Polar Capital Holdings Plc now owns 1,654,470 shares of the specialty pharmaceutical company’s stock valued at $45,614,000 after acquiring an additional 150,000 shares in the last quarter. Finally, Congress Asset Management Co. MA boosted its holdings in shares of Supernus Pharmaceuticals by 19.1% in the third quarter. Congress Asset Management Co. MA now owns 917,164 shares of the specialty pharmaceutical company’s stock valued at $25,286,000 after acquiring an additional 147,105 shares in the last quarter.

Insider Buying and Selling

In related news, VP Padmanabh P. Bhatt sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $30.21, for a total transaction of $151,050.00. Following the completion of the sale, the vice president now directly owns 8,570 shares in the company, valued at $258,899.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, VP Padmanabh P. Bhatt sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $30.21, for a total value of $151,050.00. Following the completion of the transaction, the vice president now owns 8,570 shares of the company’s stock, valued at approximately $258,899.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 12,364 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total transaction of $436,572.84. Following the completion of the transaction, the vice president now directly owns 8,570 shares of the company’s stock, valued at approximately $302,606.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,739 shares of company stock worth $1,227,433. Corporate insiders own 8.76% of the company’s stock.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $29.95 on Wednesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $21.99 and a 1-year high of $38.61. The company has a 50 day moving average price of $31.41 and a 200 day moving average price of $28.58.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.39). The business had revenue of $164.30 million for the quarter, compared to the consensus estimate of $155.03 million. Supernus Pharmaceuticals had a return on equity of 0.14% and a net margin of 0.22%. The company’s quarterly revenue was down 1.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.43 earnings per share. Sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Piper Sandler decreased their price objective on shares of Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating for the company in a report on Wednesday, February 28th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.